How to Use Your Tax Refund to Change Your Life
10 Places to Turn Your Unwanted Stuff Into Cold, Hard Cash
Bogus Weight-Loss Claims Leads to $9 Million in Fines
Week's Winners and Losers: Apple Sizzles, Microsoft Fizzles
Is Celgene the Perfect Stock?
Merck has confirmed that it halted its late-stage student of vorapaxar, a potential clot-preventing drug, after an increased risk of bleeding in some patients.